AMTAGVI Commercialization Challenges: Successfully launching and achieving significant market penetration for AMTAGVI (lifileucel) in advanced melanoma will require overcoming challenges related to physician adoption, market access, pricing and reimbursement negotiations, and competition from existing and emerging therapies.

Manufacturing and Supply Chain Complexity: The autologous nature of tumor-infiltrating lymphocyte (TIL) therapy, like AMTAGVI, involves highly complex, individualized manufacturing processes. Scaling up production, ensuring consistent quality, and managing a robust global supply chain for patient-specific products present significant operational and logistical hurdles.

Intense Competitive Landscape: Iovance faces significant competition from pharmaceutical and biotechnology companies developing other melanoma treatments, including immune checkpoint inhibitors, targeted therapies, and other cellular immunotherapies. This competition could limit AMTAGVI's market share and pricing power.